10 years ago: Sanofi-Aventis takeover


Aventis has finally accepted a bid from its French rival Sanofi Synthélabo, ending months of wrangling between the two companies and creating the world’s third largest pharmaceutical firm, after Pfizer and GlaxoSmithKline.
Aventis had for some time fought off a €45bn hostile bid from Sanofi, despite the fact that the French government had openly supported the takeover. The government had discouraged a ‘white knight’ bid from Swiss pharmaceutical firm Novartis, openly displaying its enthusiasm for a French national pharmaceutical champion. It also stressed the need for France to guarantee access to vaccines in the event of a terrorist attack.
The new group will be called Sanofi-Aventis, and will be headed by Jean-François Dehecq, Sanofi’s CEO.
Chemistry World (June 2004)

Ed.  Since 2004 Chemistry World has regularly reported on the fortunes of Sanofi-Aventis, which has developed into a global healthcare company, with acquisitions including Zentiva, Medley, Kendricks, Acambis, Symbion and Merial. It is the world’s largest producer of vaccines through its subsidiary Sanofi Pasteur. In 2011, Sanofi-Aventis acquired Genzyme and shareholders approved the change of company name to Sanofi at that year’s combined shareholder meeting.
 


Related Content

Actavis rescues Allergan with $66 billion deal

24 November 2014 Business

news image

Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price

Sanofi hostile move for Genzyme

5 October 2010 News Archive

news image

Sanofi-Aventis makes a hostile $18.5 billion takeover bid for US biotech, Genzyme

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs

Exploiting the data mine

13 August 2015 Feature

news image

Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, repor...